LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study focuses on analyzing the effect of HER2 on MHC class I antigen presentation and sensitivity to tumor-antigen specific cytotoxic T lymphocytes (CTLs) in HLA-A2.1(+) melanoma cell lines.
|
20715101 |
2011 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
As tumor antigen-specific CD4+ T cells can mediate strong therapeutic anti-tumor responses in melanoma patients we set out to establish a comprehensive screening strategy for the identification of tumor-specific CD4+ T cell epitopes suitable for detection, isolation and expansion of tumor-reactive T cells from patients.
|
21152437 |
2010 |
LINC01194
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate this, we determined the specificity of T cells from melanoma patients treated with DCs loaded with mRNA encoding a full-length tumor antigen fused to a signal peptide and an HLA class II sorting signal, allowing presentation in HLA class I and II.
|
22371843 |
2012 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive transfer of tumor-antigen-specific T(H)9 cells into both WT and Rag1(-/-) mice suppressed melanoma growth; this effect was abrogated by treatment with neutralizing antibodies to IL-9.
|
22772464 |
2012 |
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators.
|
22850568 |
2012 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the efficacy of melanoma DC-based immunotherapy is enhanced when tumor antigen-loaded DCs used for vaccination express cPs.
|
23934126 |
2013 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4) appears to be a useful biomarker to identify melanoma cells and an attractive target to apply antibody-based immunotherapy for the treatment of melanoma.
|
24258997 |
2014 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although melanoma vaccines stimulate tumor antigen-specific CD8(+) T cells, objective clinical responses are rarely observed.
|
24343228 |
2014 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we determined that TIGIT is upregulated on tumor antigen-specific (TA-specific) CD8⁺ T cells and CD8⁺ tumor-infiltrating lymphocytes (TILs) from patients with melanoma, and these TIGIT-expressing CD8⁺ T cells often coexpress the inhibitory receptor PD-1.
|
25866972 |
2015 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we discuss the roles of emerging molecular players that are involved in melanoma pathogenesis, including the functional role of the melanoma tumor antigen, p97/MFI2 (melanotransferrin).
|
26844774 |
2016 |
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that EGF G1380A and bFGF C754G gene polymorphisms were associated with the susceptibility and prognosis of malignant melanoma, and that the polymorphisms of EGF G1380A and bFGF C754G as well as the haploid TAG increased the susceptibility of malignant melanoma.
|
28219779 |
2017 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discrepancy Between Tumor Antigen Distribution and Radiolabeled Antibody Binding in a Nude Mouse Xenograft Model of Human Melanoma.
|
28380302 |
2017 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
|
29325699 |
2018 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival.
|
29744371 |
2018 |
LINC01194
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, MAP kinase inhibitors (MAPKi) strongly alter the tumor antigen expression profile over time, favoring evolution of melanoma variants cross-resistant to both T cells and MAPKi.
|
30221038 |
2018 |
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Introduction of a tumor antigen-specific T cell receptor (TCR) into patient-derived lymphocytes has already exhibited promising results for the treatment of melanoma and other malignancies in clinical trials.
|
31207210 |
2019 |